Literature DB >> 12858469

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

Marc Michel1, Cristophe Duvoux, Cristophe Hezode, Daniel Cherqui.   

Abstract

Infliximab, a chimeric anti-tumor necrosis factor-alpha monoclonal antibody, has been demonstrated to be efficient and safe in patients with active rheumatoid arthritis and in the management of severe bouts of Crohn's disease. However, the safety of infliximab has not been evaluated in patients infected with hepatitis B virus. We report the case of a 28-year-old woman, with a positive hepatitis B virus surface antigen, who developed fulminant hepatitis 2 weeks after receiving a second infliximab infusion for a refractory adult onset Still's disease.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12858469

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  49 in total

1.  Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls.

Authors:  Mustafa Erhan Altunöz; Ebubekir Senateş; Atakan Yeşil; Turan Calhan; Ayşe Oya Kurdaş Ovünç
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

2.  Still disease and the liver-an underappreciated association.

Authors:  Kieron B L Lim; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

Review 3.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

4.  Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?

Authors:  Manuel Ramos-Casals
Journal:  Nat Rev Rheumatol       Date:  2010-11       Impact factor: 20.543

Review 5.  Diagnosis and management of adult onset Still's disease.

Authors:  P Efthimiou; P K Paik; L Bielory
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

6.  Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

Authors:  Yoshitaka Ueno; Shinji Tanaka; Masaru Shimamoto; Yoshihiro Miyanaka; Toru Hiyama; Masanori Ito; Yasuhiko Kitadai; Masaharu Yoshihara; Masaharu Sumii; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

Review 7.  Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.

Authors:  L H Calabrese; N N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

8.  Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

Authors:  Gunda Millonig; Michaela Kern; Othmar Ludwiczek; Karin Nachbaur; Wolfgang Vogel
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

9.  Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.

Authors:  Sophia Li; Primal P Kaur; Virginia Chan; Steven Berney
Journal:  Clin Rheumatol       Date:  2009-03-17       Impact factor: 2.980

Review 10.  Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.

Authors:  Pilar López-Serrano; Jose Lázaro Pérez-Calle; Maria Dolores Sánchez-Tembleque
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.